UNSPSC 51241136: Unoprostone isopropyl ester

This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C25H44O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M161S5O5P, chemically known as isopropyl z-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)hept-5-enoate, d-, but more generally known as unoprostone isopropyl ester, which bears US NIH Compound Identifier 5282175.

European Medicines Agency schedules unoprostone isopropyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11381MIG. Most nations, for tariff purposes, schedule unoprostone isopropyl ester under HS 29375000. SMILES: CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O)O.

UNSPSC 51241136 Unoprostone isopropyl ester is a Commodity code representing a specific pharmaceutical product—an ophthalmic prostaglandin analog—that state and local governments procure through cooperative purchasing vehicles and multi-source pharmaceutical contracts. The work being solicited under this code involves manufacturers and distributors supplying identified generic and brand-name pharmaceuticals with specific National Drug Codes (NDCs) to state and local health agencies, correctional facilities, and other government healthcare systems through established pharmaceutical supply chains and authorized wholesalers. State and local governments buy under this code primarily through cooperative purchasing alliances and multi-state pooled procurement agreements rather than through individual agency RFPs; the issuing bodies include state departments of health and administration, state prison systems, county health departments, and municipal healthcare facilities that participate in pooled purchasing agreements to leverage volume and standardize pricing across jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with detailed product information including NDC codes, SKUs, and UPCs. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence. The contract term is two years for new responders with optional extensions, and pricing will be evaluated on competitiveness (75 percent), fixed pricing for the contract term (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and administrative data format requirements (5 percent).